The study met the primary endpoint demonstrating superiority to daily TransCon in terms of annualized height velocity (AHV) at week 52. Specifically, the treatment difference was 0.86 cm/year, a statistically significant result (p=0.0088). Also, the separation was statistically valid from week 26 onward.

Have you seen the article Forbes wrote about the ASDN Flying Passenger Drone and its technology?

The safety profile was on par with the daily regimen.

Weekly dosing is a major advantage since GHD patients need therapy over a period of years.

The data will be presented at ENDO 2019 on March 24.

Topline data from a second Phase 3, fliGHt, should be available next quarter. The company expects to file a U.S. marketing application in H1 2020.

Management will host a conference call this morning at 8:00 am ET to discuss the results.
Bed, Bath & Beyond (NASDAQ:BBBY) drifts lower after a Monday morning downgrade from Barclays to an Underweight rating from Equal Weight.

Why Investors Are Calling ASDN the BBBY of the Sky!

The investment firm isn’t seeing signs of a turnaround by BBBY. “It will be highly difficult for the company to build a home furnishing/decor business, which appears to be a critical factor in the ultimate success of a turnaround,” warns analyst Matthew McClintock.

Shares of Bed Bath & Beyond are down 2.94% in premarket trading to $16.20 vs. a 52-week trading range of $10.46 to $23.28.